Navigation Links
Neurocrine Biosciences Amends Corporate Headquarters Lease
Date:10/1/2009

SAN DIEGO, Oct. 1 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company has entered into an amendment to its facility lease agreement. The amendment eliminates approximately 70,000 square feet of leased space.

"We worked with our landlord in a collaborative manner to reduce our leasing obligation and to allow them to directly market the property, while at the same time minimizing the cash flow impact to Neurocrine," said Timothy P. Coughlin, Vice President and Chief Financial Officer of Neurocrine Biosciences. "This is a significant first step in reducing our fixed real estate cost structure, reducing our overall obligation by approximately $27 million."

Under the terms of the lease amendment, Neurocrine will vacate the front building of the two building campus and will make an immediate payment of $4 million to the landlord as an initial release fee. Additionally, the Company has agreed to make certain rent payments and rent differential payments with respect to the released space.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH), irritable bowel syndrome (IBS) and other neurological and endocrine related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com

SOURCE Neurocrine Biosciences, Inc.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
2. Neurocrine Biosciences Secures Committed Equity Financing Facility
3. Neurocrine Biosciences Reports Second Quarter 2009 Results
4. Webcast Alert: Neurocrine Biosciences Announces 2nd Quarter 2009 Earnings Results
5. Neurocrine Biosciences Announces Conference Call and Webcast to Present Second Quarter 2009 Financial Results
6. Neurocrine Biosciences to Present at the 8th Annual Needham Life Sciences Conference
7. Neurocrine Biosciences to Present at the Deutsche Bank 34th Annual Health Care Conference
8. Neurocrine Biosciences Reports First Quarter 2009 Results
9. Neurocrine Announces Work Force Restructuring
10. Neurocrine Biosciences to Present at the 16th Annual Future Leaders in the Biotech Industry Conference
11. Neurocrine Biosciences to Present at the Cowen and Company 29th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... The November 2014 issue of BioTechniques ( ... journal featuring the following articles:, , ... in the retina , DNA from fingermarks ... chromogenic substrates in zebrafish , Re-use of ... , Nuclear LC3-positive puncta in stressed cells ...
(Date:11/21/2014)... , Nov. 20, 2014 Polaris ... been dosed in its Phase 1 trial of ... for the treatment of malignant pleural mesothelioma (MPM) ... is conducting clinical trials on ADI-PEG 20, both ... for the treatment of several other indications, including ...
(Date:11/18/2014)... November 17, 2014 RPS Diagnostics ... tests – today announces its third annual partnership ... (CDC) Get Smart About Antibiotics Week from November ... a national campaign designed to highlight the coordinated ... and non-profit and for-profit partners to provide education ...
(Date:11/18/2014)... 18, 2014 American Process Inc. ... formed a partnership with researchers at Georgia Institute ... Technology, and the USDA’s Forest Products Laboratory to ... nanocellulose. Nanocellulose is a rapidly emerging high performance ... project is to replace heavy steel structures within ...
Breaking Biology Technology:BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 2BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 3Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 3American Process Inc. Announces Partnership to Develop Ultra-Strong, Lightweight Automotive Components Using Nanotechnology from Nature 2American Process Inc. Announces Partnership to Develop Ultra-Strong, Lightweight Automotive Components Using Nanotechnology from Nature 3
... Oct. 24 Favrille, Inc. (OTC,Bulletin Board: FVRL) announced ... for a reverse merger whereby Favrille would acquire,all of ... in a stock for stock merger that would result ... proposed transaction is,consummated on the terms set forth in ...
... five years after Jim Rider, the first American patient to receive ... patient milestone. , ... Bremen, Germany (PRWEB) October 24, ... worse, and the knowledge that many treatments are just not available ...
... p.m. EST, HOPKINTON, Mass., Oct. 23 ... conduct a conference call discussing the,company,s third quarter ... Monday,November 10. Kevin Hrusovsky, President and Chief Executive ... the call. Management will,discuss operational and financial results ...
Cached Biology Technology:Favrille Announces Execution of Non-binding Term Sheet for a Merger Transaction 2Stenum Hospital Does its 600th American Disc Replacement Surgery 2Caliper Life Sciences' Third Quarter 2008 Financial Results Conference Call Notice 2
(Date:11/4/2014)... LAKE CITY, Nov. 5, 2014 – University of Utah ... enzymes to help jet fuel produce electricity without needing ... be used to power portable electronics, off-grid power and ... online today in the American Chemical Society journal ... electricity through a chemical reaction between a fuel and ...
(Date:11/4/2014)...   3D scanner developer targets ... Fuel3D , a developer of 3D scanning solutions, today announced ... (£4 million). This funding builds on the company,s initial $2.6 ... the way for the commercial launch of the company,s consumer ... led by Chimera Partners and will be used to ramp-up ...
(Date:11/3/2014)... , Nov. 3, 2014  NeuroSigma ® ... -based life sciences company focused on commercialization of ... for the treatment of neurological and neuropsychiatric ... Industrial Property has issued a Notice of Allowance ... application is co-owned by NeuroSigma and the Regents ...
Breaking Biology News(10 mins):Jet-fueled electricity at room temperature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... Researchers at the University of Newcastle, England, ... the United States have revealed a large reservoir of ... analysis of blood samples from almost 3,000 infants born ... in 200 individuals in the general public harbor mitochondrial ...
... the International Primatological Society (IPS) Lifetime Achievement Award for ... was presented at the 12th Congress of the IPS ... also be given the Leakey Prize for revolutionizing our ... Foundation. He shares the prize with Jane Goodall. Nishida ...
... While the CDC recently reported that more moms than ever ... moms do not stick with it as long as they ... breastfeed, the new Brigham Young University study found that only ... short of the federal government,s goal to hit 50 percent ...
Cached Biology News:Large reservoir of mitochondrial DNA mutations identified in humans 2Springer editor Toshisada Nishida winner of 2 prestigious primatology awards 2New breastfeeding study shows most moms quit early 2
Rat monoclonal [HK5.3] to B7 RP1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
Rabbit polyclonal to ZFP200 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGKSFNHKTNLNKHER (Human) Entrez Gene ID: 7752 Swiss Protein ID: P98182...
BACE (CT) rabbit polyclonal antibody...
Rabbit polyclonal to MA2 ( Abpromise for all tested applications). entrezGeneID: 10687 SwissProtID: Q9UL42...
Biology Products: